Sydbank positive despite muted growth for Darzalex

Partner J&J's interim report shows that sales of Genmab’s cancer drug Darzalex doubled in Q3. However, the growth rate is lower compared to earlier this year, whivh has caused a drop in Genmab's share price. But despite the cancer hope’s failure to meet expectations, Sydbank still calls the development positive.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

GSK får FDA nik til potentiel revolutionerende HIV-behandling

GSK har fået grønt lys fra de amerikanske lægemyndigheder, FDA, til selskabets mest lovende HIV-middel. Tilladelsen kan være indledningen til et paradigmeskifte inden for HIV-behandling, idet behandlingen reducerer antallet af lægemidler, patienterne behøver at tage.

Latest Top picks in English

Related articles